These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33749049)

  • 41. Association between chemotherapy response and rate of disease progression in disseminated melanoma.
    Joensuu H
    Br J Cancer; 1991 Jan; 63(1):154-6. PubMed ID: 1989656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
    Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
    Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
    Nashan D; Müller ML; Grabbe S; Wustlich S; Enk A
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1305-18. PubMed ID: 17958834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
    Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
    Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination chemotherapy for disseminated malignant melanoma.
    Abbott KL; Harman GS
    Anticancer Drugs; 1995 Aug; 6(4):489-97. PubMed ID: 7579552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
    Hernberg MM; Hahka-Kemppinen MH; Pyrhönen SO
    Melanoma Res; 2004 Dec; 14(6):493-500. PubMed ID: 15577320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma.
    Lopez M; Perno CF; Di Lauro L; Papaldo P; Ganzina F; Barduagni A
    Invest New Drugs; 1984; 2(3):319-22. PubMed ID: 6392148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
    Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Chemotherapy of malignant melanoma--current status].
    Karg C; Garbe C; Orfanos CE
    Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
    Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
    Kiebert GM; Jonas DL; Middleton MR
    Cancer Invest; 2003; 21(6):821-9. PubMed ID: 14735685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
    Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
    Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
    Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R
    Melanoma Res; 2003 Feb; 13(1):87-91. PubMed ID: 12569290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma.
    Polyzos A; Legha SS; Burgess AM; Benjamin RS; Bodey GP
    Invest New Drugs; 1988 Apr; 6(1):57-61. PubMed ID: 3410667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.